Bayer Rapidpoint 405 System
by Bayer Diagnostics Corp. 510(k)
Active
510(k) K020616
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK020616 | Date17 Jul 2002 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Recalls
-
- Terminated Z-2927-2018
- Terminated Z-2928-2018
Therapeutic levels (1mg/mL and 2mg/mL) of Hydroxocobalamin may interfere with tHb and some of the CO-Ox fractions that are reported on the RAPIDPoint and RAPIDLab Blood Gas systems indicated. This may cause lower than expected values for carboxyhemoglobin (fCOHb) and methemoglobin (fMetHb). A negative interference with fCOHb has the potential to alter the medical assessment of the patient and may withhold necessary follow-up treatment and/or initiate cessation of medication in response to elevated fMetHb levels.
-
- Terminated Z-2479-2015
When both ports (Serial and Ethernet) are configured to transmit data, the data stream from one port could potentially affect the data stream from the other port causing the data management system to include either: duplicate data, missing data, or data from a different patient.
-
- Terminated Z-0066-04
Potential for bias shift in pO2 values due to air bubble in sample path
Specification
- 510(k) Number
- FDA Product Code
- GKR
- Device Class
- Class II
- Regulation
- 21 CFR Part 864.5620
- Advisory Committee
- Hematology
- FDA Decision
- SESE Substantially Equivalent